All In Biotech

Drug Trial Radar · NCT06680947

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb, Effcacy and Safety Study of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy in Adult Subjects With Severe Asthma

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Dec 20, 2024

Primary completion

Feb 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Conditions

  • Asthma

Interventions

  • 610Drug

    Subcutaneously injection.

  • 610Drug

    Subcutaneously injection.

  • PlaceboDrug

    Subcutaneously injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at week 52Time frame: Baseline (Day 1) and at week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.